ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Accendo Markets Weekly Roundup, 24 May 2013 - QE3 taper tantrum fuels healthy correction

Share On Facebook
share on Linkedin
Print

A roller-coaster ride for markets this week and a perfect example of how important central bank communication (read US Federal Reserve) has become and how markets can move indiscriminately on changes in sentiment regarding the future of the highly accommodative monetary policy  (read Fed’s QE3), something that has supported the global rally and recovery hopes since the middle of last year as opposed to improving fundamentals. While headlines focus on the big share price falls of the last 2 days from near/above all-time highs, bear in mind that the reversal comes after a very steep run-up which had been displaying warning signs of exhaustion – something we highlighted earlier in the week.

©

This does not contain personal recommendations or advice. You can lose more than your initial investment when trading leveraged products.

Accendo Markets is an online trading services provider, offering CFDs, spread betting and forex to retail (private) clients. Accendo Markets was established in 2007 and has since gone on to win various awards including “2012 Winner of Best Execution only CFD provider” at City of London Wealth Management awards. Accendo Markets Ltd. is authorised and regulated by the Financial Services Authority (FSA).

Register now for your FREE trading Guide

It’s not been pretty, but it could have been worse. The round trip on the FTSE 100 also puts it down just 1.0% over the week. The 3.5% decline from 13.5yr highs has been sharp, and no doubt hurt those who had only recently joined the rally, but must be looked at in relation to 1-month gains of 10%. This had taken the index to within 60pts of all-time highs, helped by easy money policy and an appetite for better returns from equities over bonds. The rally from last June also remains intact, and note that gains of 14% to last September and another 16% to March were both digested by retraces of 5%.

This correction thus looks healthy and could even go as far as 6,550 before we resume higher. Markets are scared of the Fed taking away the QE3 punchbowl as US growth/jobs data improves, but removal of this market prop is a way off yet. Data remains mixed and Fed Chairman Bernanke has highlighted flexibility to both increase and decrease the rate of intervention. Until we see the extent of the first tapering/trimming to QE3 as data improves, concern looks overdone. Are we really to fret about a slight trimming to QE3? Some bad data could easily see it reversed and even increased soon after. It’s still early days, but be prepared for continued swings.

Few stocks have helped support the index this week, with BP’s 1.6% rise and positive 5.3pt index contribution the best showing, helped by news on production and plans in Iraq and despite volatility in the price of oil, as the USD rallied on the possibility of the US Fed reducing its dollar-weakening asset purchases (QE3) sooner than expected on better US macro data; making dollar-denominated commodities more expensive. Nonetheless, note the limited move in the price of Gold, with less demand for the yellow metal as a safehaven as fears of global collapse recede and the need for it as an inflation hedge has become redundant, for now anyway.

No surprise that the other helpers were Defensives, living up to their name, with GlaxoSmithKline (GSK; +1.5%; 4.8pts) helped by and the award of up to $200m by the US to develop a new antibiotic, Imperial Tobacco (IMT; +4.5%, +3.9pts) and Reckitt Benckiser (RB; +2.3%; +3.0pts) both benefiting from the general market rise and search for yield before the market reversal, and Shire Pharma (SHP; 5.5%; 2.5pts) continuing its recovery to February highs, helped by another broker update early in the week.

Those weighing most on the index included heavyweight HSBC (HSBA; -4.0%; -20.5pts) with appetite dented by growth concerns in Asia where the bank has a big presence after weak China data and despite some positive broker comment with some suggestions of weakness ahead of today’s AGM and the possibility that the bank’s proposed US settlement over money laundering could be rejected, leaving it open to criminal charges and even a ban from the US. SAB Miller (SAB; -5.23%; -10.6pts) suffered after disappointing FY results added to negative momentum from the prior week while Standard Chartered (STAN; -5.0%; -7pts) was hindered by general market weakness and Chinese/Asian data and Lloyds Banking Group (LLOY; -4%; -6pts) saw market weakness on the Fed tapering fears overriding good news on capital requirements and broker upgrades. Vodafone (VOD; -1.45%; -5.1pts) turned back from 12yr highs after FY results which included no news on its Verizon Wireless JV stake.

It’s been a busy week and I for one will be thankful for a three day weekend to digest and further reflect upon whether the long-term rally has legs or indeed this correction is the start of something more significant. Much to ponder over. Let’s see what I’m thinking by Tuesday on CNBC’s Squawk Box Europe and what the drivers are for the new week.

As always, have a great weekend.

For any commentary/analyst opinion on anything CFD/Spread Bet/financial markets-related, please contact research@accendomarkets.com

www.accendomarkets.com

Risk warning
CFD trading, spread betting and Forex trading can result in losses exceeding your original deposit. Ensure you understand the risks, seek independent financial advice if necessary. Authorised and regulated by the Financial Services Authority.

 

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

Accendo Markets is an online trading services provider, offering CFDs, spread betting and forex to retail (private) clients. Accendo Markets was established in 2007 and has since gone on to win various awards including "2012 Winner of Best Execution only CFD provider" at City of London Wealth Management awards. Accendo Markets Ltd. is authorised and regulated by the Financial Services Authority (FSA). Register now for your FREE trading Guide Risk warning CFD trading, spread betting and Forex trading can result in losses exceeding your original deposit. Ensure you understand the risks, seek independent financial advice if necessary. Authorised and regulated by the Financial Services Authority.
This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com